Maternal antioxidant supplementation does not reduce the incidence of phenytoin-induced cleft lip and related malformations in rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 74, Issue 2, 2005, Pages 201-206

  Abela, Dominique ^a   Howe, Andrew M ^a   Oakes, Diana A ^a   Webster, William S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antioxidants; Cleft lip; Free radicals; Hypoxia; Phenytoin; Reoxygenation

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CASEIN; CELLULOSE; CHOLINE; DEXTRIN; METHIONINE; MINERAL; PHENYTOIN; RAPESEED OIL; STARCH; SUCROSE; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIRTH DEFECT; BODY WEIGHT; BRADYCARDIA; CELL CYCLE; CLEFT LIP; DIET SUPPLEMENTATION; EMBRYO; FETUS; FOOD INTAKE; GENETIC TRANSCRIPTION; GESTATIONAL AGE; HYPOXIA; MAXILLA HYPOPLASIA; NONHUMAN; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROTECTION; RAT; RAT STRAIN; REOXYGENATION; RISK FACTOR; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; ANTIOXIDANTS; ASCORBIC ACID; BODY WEIGHT; CLEFT LIP; DIET; EATING; FEMALE; MALE; MAXILLA; PHENYTOIN; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS; UBIQUINONE; VITAMIN E;

EID: 18244366867     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20037     Document Type: Article

References (37)

1. Abela D. 2003. Phenytoin teratogenesis: drug-induced embryonic hypoxia. Honour Thesis, University of Sydney: Sydney, Australia. p 1-99.
2. Abrishamchian AR, Khoury MJ, Calle EE. 1994. The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case-control study. Genet Epidemiol 11: 343-351.
3. Azarbayjani F, Danielsson BR. 1998. Pharmacologically induced embryonic dysrhythmia and episodes of hypoxia followed by reoxygenation: a common teratogenic mechanism for antiepileptic drugs? Teratology 57:117-126.
4. Azarbayjani F, Danielsson BR. 2001. Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage. Teratology 63:152-160.
5. Azarbayjani F, Danielsson BK. 2002. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related teratogenic mechanism for antiepileptic drugs? Epilepsia 43:457-408.
6. Bossenmeyer-Pourie C, Lievre V, Grojean S, Koziel V, Pillot T, Daval JL. 2002. Sequential expression patterns of apoptosis- and cell cycle-related proteins in neuronal response to severe or mild transient hypoxia. Neuroscience 114:869-882.
7. Cederberg J, Martin Siman C, Eriksson UJ. 2001. Combined treatment with vitamin E and vitamin C decreases oxidative stress and improves fetal outcome in experimental diabetic pregnancy. Pediatr Res 49:755-762.
8. Danielsson BR, Webster WS. 1997. Cardiovascular active drugs. In: Kavlock RJ, Daston GP, editors. Drug toxicity in embryonic development. II: Advances in understanding mechanisms of birth defects: mechanistic understanding of human developmental toxicants. Berlin: Springer, p 161-190.
9. Danielsson BR, Azarbayjani F, Skold A-C, Webster WS. 1997. Initiation of phenytoin teratogenesis: pharmacologically induced embryonic bradycardia and arrhythmia resulting in hypoxia and possible free radical damage at reoxygenation. Teratology 56:271-281.
10. Danielsson BR, Skold A-C, Azarbayjani F, Ohman I, Webster WS. 2000. Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats. Toxicol Appl Pharmacol 163:164-175.
11. Danielsson BR, Skold A-C, Azarbayjani F 2001. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharma Des 7:787-802.
12. Danielsson BR, Iansdell K, Patmore L, Tomson T. 2003. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 55:147-157.
13. Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS. 1996. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 78:15-25.
14. Dravet C, Julian C, Legras C, Magaudda A, Guerrini R, Genton P, Soulayrol S, Giraud N, Mesdjian E, Trentin G, Roger J, Avme S. 1992. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 42(Suppl 5):75-82.
15. Fantel AG, Barber CV, MacKler B. 1992. Ischemia/reperfusion: a new hypothesis for developmental toxicity of cocaine. Teratology 46: 285-292.
16. Fantel AG, Person RE, Tumble KW, Nguyen TD, Markler B. 1995. Studies of mitochondria in oxidative embryotoxicity. Teratology 52:190-195.
17. Fantel AG. 1996. Reactive oxygen species in developmental toxicity: review and hypothesis. Teratology 53:196-217.
18. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL, Dang CV. 2001. Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276:7919-7926.
19. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. 2003. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23:359-369.
20. Harbison RD, MacDonald JS, Sweetman BJ, Taber D. 1977. Proposed mechanism for dephenylhydantoin-induced teratogenesis [Abstract]. Pharmacologist 19:179.
21. Howe AM, Lipson AH, Sheffield LJ, Haan EA, Halliday JL, Jenson F, David DJ, Webster WS. 1995. Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Am J Med Genet 58:238-244.
22. Kwong LK, Kamzalov S, Rebrin I, Bayne A-CV, Jana CK, Morris P, Forster MJ, Sohal RS. 2002. Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation and oxidative stress in the rat. Free Radic Biol Med 33:627-638.
23. Martz F, Failinger C, Blake DA. 1977. Phenytoin teratogenesis: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J Pharmacol Exp Ther 203: 231-239.
24. Millicovsky G, Johnston MC. 1981a. Maternal hyperoxia greatly reduces the incidence of phenytoin-induced cleft lip and palate in A/J mice. Science 212:671-672.
25. Millicovsky G, Johnston MC. 1981b. Hyperoxia and hypoxia in pregnancy: simple experimental manipulation alters the incidence of cleft lip and palate in CL/Fr mice. Proc Natl Acad Sci USA 78:5722-5723.
26. Nobile M, Vercellino P. 1997. Inhibition of delayed rectifier K+ channels by phenytoin in rat neuroblastoma cells. Br J Pharmacol 120: 647-652.
27. Reeves PG, Nielsen FH, Fahey GC. 1993. AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition ad hoc witting committee on the reformulation of the AIN-76A rodent diet. J Nutr 123:1939-1951.
28. Sanyal S, Wells PG. 1993. Reduction in phenytoin teratogenicity by pretreatment with the antioxidant D-a-tocopherol acetate (vitamin E) in CD-1 mice [Abstract]. Toxicologist 13:252.
29. Sulik KK, Johnston MC, Ambrose LJ, Dorgan D. 1979. Phenytoin (dilantin)-induce cleft lip and palate in A/J mice: a scanning and transmission electron microscopic study. Anat Rec 195:243-255.
30. Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ. 1996. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res 79:79-85.
31. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR. 1996. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 53: 168-175.
32. Wellfelt K, Sköld AC, Wallin A, Danielsson BR. 1999. Teratogenicity of the class III antiarrhythmic drug almokalant: role of hypoxia and reactive oxygen species. Reprod Toxicol 13:93-101.
33. Wells PG, Vo HP. 1989. Effects of the tumor promoter 12-O- tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice. Toxicol Appl Pharmacol 97:398-405.
34. Wells PG, Zubovits JT, Wong ST, Molinari LM, Ali S. 1989. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase. Toxicol Appl Pharmacol 97:192-202.
35. Winn LM, Wells PG. 1999. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radical Biol Med 26:266-274.
36. Yu WK, Wells PG. 1995. Evidence for lipoxygenase-catalysed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase and in vivo experiments using pregnant CD-1 mice. Toxicol Appl Pharmacol 131:1-12.
37. Zimmerman EF, Potturi RB, Resnick E, Fisher JE. 1994. Role of oxygen free radicals in cocaine-induced vascular disruption in mice. Teratology 49:192-201.